AAV Vector Gene Therapy for JPH2 Cardiomyopathy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hypertrophic cardiomyopathy and dilated cardiomyopathy associated with Junctophilin-2 (JPH2) deficiencies are ineffective, highlighting an unmet need for targeted therapies to address these serious heart conditions.

Innovation Solution

A gene therapy approach using a vector expressing JPH2 or a functional variant, delivered via a recombinant adeno-associated virus (rAAV) vector with cardiac-specific promoters like Myosin Heavy-chain Creatine Kinase 7 (MHCK7) or cardiac troponin T, to increase JPH2 expression in cardiomyocytes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If pharmacological therapies and cardiac ablation are used for JPH2-deficient cardiomyopathy, then treatment is provided, but the treatment remains ineffective

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment applicability to JPH2 deficiency

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses an AAV vector as an intermediary delivery system to transport the JPH2 gene into cardiomyocytes. This mediator enables targeted gene delivery to the specific cell type affected by the disease, overcoming the ineffectiveness of conventional pharmacological approaches that cannot address the underlying genetic deficiency.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the fundamental parameter of treatment from pharmacological intervention to genetic intervention. By introducing a functional JPH2 gene via AAV vector, the treatment addresses the root cause (gene deficiency) rather than merely managing symptoms, thereby achieving effectiveness where previous treatments failed.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If a gene therapy approach using rAAV vector is used, then JPH2 expression is increased in cardiomyocytes, but the complexity of the treatment increases

Engineering Contradiction:

ImproveJPH2 expression levelVSAvoidtreatment system complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The AAV vector serves multiple functions: it protects the genetic material during delivery, enables targeted infection of cardiomyocytes, and provides long-term stable expression of the transgene. This multi-functionality consolidates what would otherwise require multiple separate systems into a single therapeutic agent, managing complexity while achieving reliable gene expression.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The cardiac-specific promoter within the expression cassette enables the transgene to be automatically activated in the correct cell type (cardiomyocytes) without requiring external regulatory mechanisms. This self-regulating feature simplifies the treatment system by eliminating the need for complex external control systems to ensure tissue-specific expression.

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS20240335565A1Junctophilin-2 (JPH2) gene therapy using AAV vector

Publication Date: 2024.10.10 SPACECRAFT SEVEN LLC

AI summary

Provided herein is a gene therapy for JPH2 (Junctophilin-2), e.g., using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.